SHR2554
SHR2554 is a pharmaceutical drug with 11 clinical trials. Currently 3 active trials ongoing. Historical success rate of 66.7%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
6
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
66.7%
2 of 3 finished
33.3%
1 ended early
3
trials recruiting
11
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
SHR-1701 Combined with SHR2554 and BP102 for MCRC
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
Clinical Trials (11)
PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
SHR-1701 Combined with SHR2554 and BP102 for MCRC
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects
All 11 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 11